Publications by authors named "Maarten Treur"

Claim this Profile
A
A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France.
Kaspar Nieland, Antoine Labbé, Cedric Schweitzer, Gaetan Gicquel, Joris Kleintjens, Maarten Treur

PLoS One· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma.
Elisabeth F P Peterse, Elisabeth J M Verburg-Baltussen, Alexa Stewart, Fei Fei Liu, Christopher Parker, Maarten Treur

Pharmacoecon Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Roman Hájek, Jiri Jarkovsky, Vladimír Maisnar, Ludek Pour, Ivan Špička, Maarten Treur

Clin Lymphoma Myeloma Leuk· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.
Marieke Heisen, Maarten J Treur, Harald E Heemstra, Eric B W Giesen, Maarten J Postma

J Med Econ· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis.
Floortje van Nooten, Maarten Treur, Krystallia Pantiri, Malcolm Stoker, Mata Charokopou

Clin Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.
Kirsten Y Westerhout, Walter Bouwmeester, Inge Duchesne, Marta Pisini, Marjanne A Piena, Maarten Treur

Clinicoecon Outcomes Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Kirsten Westerhout, Maarten Treur, Angelika Mehnert, Katie Pascoe, Imran Ladha

J Med Econ· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.
Francesca Pierotti, Ilaria Palla, Maarten Treur, Lara Pippo, Giuseppe Turchetti

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.
Istvan M Majer, Fiona Gaughran, Christophe Sapin, Maud Beillat, Maarten Treur

J Mark Access Health Policy· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
Hiroyo Kuwabara, Kirsten Westerhout, Maarten Treur, Karin Cerri, Joerg Mahlich

J Med Econ· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Michael Tempest, Christophe Sapin, Maud Beillat, Paul Robinson, Maarten Treur

J Ment Health Policy Econ· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
Bram G Verheggen, Richard Lee, Michelle M Lieuw On, Maarten J Treur, Marc F Botteman

J Med Econ· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics.
Kimbach Tran Carpiuc, Gianantonio Rosti, Fausto Castagnetti, Maarten Treur, Jennifer Stephens

Onco Targets Ther· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.
Maarten Treur, Bart Heeg, Hans-Jürgen Möller, Annette Schmeding, Ben van Hout

BMC Health Serv Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis